Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, and Active-controlled Parallel Study to Evaluate the Efficacy and Safety of QR12000 Compound Tablets and Sacubitril/valsartan Tablets in Patients with Moderate to Severe Essential Hypertension

NCT06716970 is registered in ClinicalTrials.gov with Wuhan Createrna Science and Technology Co., Ltd as lead sponsor.

NCT NCT06716970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06716970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, and Active-controlled Parallel Study to Evaluate the Efficacy and Safety of QR12000 Compound Tablets and Sacubitril/valsartan Tablets in Patients with Moderate to Severe Essential Hypertension
Lead sponsor
Wuhan Createrna Science and Technology Co., Ltd
Phase
Phase 3
Overall status
Not yet recruiting
Start date
December 30, 2024
Completion date
February 28, 2027
Enrollment
810 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension